Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $5.1 million.

  • Kyntra Bio's Accounts Payables fell 4486.9% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 4486.9%. This contributed to the annual value of $5.1 million for FY2024, which is 6790.47% down from last year.
  • Latest data reveals that Kyntra Bio reported Accounts Payables of $5.1 million as of Q3 2025, which was down 4486.9% from $10.5 million recorded in Q2 2025.
  • Over the past 5 years, Kyntra Bio's Accounts Payables peaked at $71.3 million during Q1 2023, and registered a low of $4.4 million during Q1 2024.
  • Over the past 5 years, Kyntra Bio's median Accounts Payables value was $19.2 million (recorded in 2023), while the average stood at $21.5 million.
  • Per our database at Business Quant, Kyntra Bio's Accounts Payables skyrocketed by 87682.95% in 2021 and then crashed by 9389.33% in 2024.
  • Kyntra Bio's Accounts Payables (Quarter) stood at $26.1 million in 2021, then grew by 17.86% to $30.8 million in 2022, then tumbled by 48.7% to $15.8 million in 2023, then crashed by 67.9% to $5.1 million in 2024, then grew by 0.57% to $5.1 million in 2025.
  • Its Accounts Payables stands at $5.1 million for Q3 2025, versus $10.5 million for Q2 2025 and $7.3 million for Q1 2025.